NASDAQ · SANA
Healthcare · Biotechnology
$2.75
Down-$0.04 (-1.56%)
Updated Oct 7, 2026, 7:26 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SANA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
SANA closed at $2.75 after 21 trading sessions, down 20.29% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $2.94 | $2.975 | $2.74 | $2.75 | 3.76M |
| Oct 5, 2026 | $2.90 | $2.93 | $2.82 | $2.88 | 5.39M |
| Oct 2, 2026 | $2.95 | $3.00 | $2.855 | $2.89 | 3.5M |
| Oct 1, 2026 | $2.89 | $3.05 | $2.85 | $2.89 | 3.77M |
| Sep 30, 2026 | $2.97 | $3.045 | $2.855 | $2.915 | 3.25M |
| Sep 29, 2026 | $2.945 | $3.055 | $2.89 | $2.91 | 3.05M |
| Sep 28, 2026 | $2.92 | $2.98 | $2.86 | $2.93 | 2.27M |
| Sep 25, 2026 | $2.96 | $3.00 | $2.90 | $2.945 | 2.88M |
| Sep 24, 2026 | $3.04 | $3.047 | $2.88 | $2.96 | 3.51M |
| Sep 23, 2026 | $3.33 | $3.33 | $3.014 | $3.08 | 3.84M |
| Sep 22, 2026 | $3.15 | $3.3599 | $3.10 | $3.33 | 7.17M |
| Sep 21, 2026 | $3.14 | $3.16 | $3.04 | $3.10 | 2.01M |
| Sep 18, 2026 | $3.09 | $3.11 | $3.02 | $3.10 | 7.41M |
| Sep 17, 2026 | $3.08 | $3.275 | $3.055 | $3.10 | 2.92M |
| Sep 16, 2026 | $3.17 | $3.21 | $2.865 | $2.92 | 9.72M |
| Sep 15, 2026 | $3.20 | $3.20 | $3.075 | $3.16 | 2.47M |
| Sep 14, 2026 | $3.135 | $3.25 | $3.10 | $3.20 | 2.38M |
| Sep 11, 2026 | $3.13 | $3.165 | $3.01 | $3.13 | 3.28M |
| Sep 10, 2026 | $3.10 | $3.19 | $3.00 | $3.09 | 4.62M |
| Sep 9, 2026 | $3.51 | $3.525 | $3.16 | $3.17 | 8.65M |
| Sep 8, 2026 | $3.78 | $3.83 | $3.395 | $3.45 | 4.99M |
The latest Smart Investors Daily articles mentioning SANA.
Company
Market Activity
Research & News
SANA research
Company profile and research snapshot.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | B of A Securities | Buy | — |
| Apr 14, 2026 | Wedbush | Outperform | — |
| Mar 4, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 6, 2026 | B of A Securities | Buy | — |
| Nov 7, 2025 | Wedbush | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 14, 2026
Sana Biotechnology, Inc. (SANA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:50 PM EDTCompany ParticipantsSteven Harr -...
SeekingAlpha · Sep 10, 2026
SeekingAlpha · Sep 10, 2026
Sana Biotechnology, Inc. (SANA) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 9:30 AM EDTCompany ParticipantsSteven Harr - President, CEO...
Yahoo · Sep 1, 2026
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update. Sana will present at the 2026 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Tuesday, September 8, 2026.Sana will present at Citi’s 2026 Biopharma Back-to-School Conf
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SANA.
